When technological innovation meets deep cultivation in industry, it is precisely the convergence of innovative paths and new development journeys.

On the afternoon of June 14, 2025, a group of students from the second phase of the School of Business, Southern University of Science and Technology's Technology Management Scholars program visited the company, embarking on a visit and exchange activity that combined industrial depth and academic value. Company General Manager Yao Xiaodong led the students on a site visit to the production workshop, and Chairman Jing Yue provided a comprehensive introduction to the company's development history and core advantages. They also engaged in in-depth discussions with the students on innovation in the biopharmaceutical industry, full-industry chain layout, and future strategies, sparking cross-border fusion of ideas.

Workshop Exploration: Decoding the Hard-Core Strength of "Made in China" Biopharmaceutical Manufacturing

At around 4 pm, the students from the second phase arrived at the company. Led by General Manager Yao Xiaodong, the students systematically toured the company's production line, pilot workshop, and quality inspection laboratory. "This is the first base in the domestic antiserum industry to adopt isolator aseptic filling technology. Each vial of tetanus antitoxin (TAT) must undergo strict procedures such as plasma digestion and antibody separation and purification." Yao Xiaodong explained. Alongside the production line, the students directly observed the entire process from immune horse plasma to finished preparations. Automated filling equipment was operating efficiently at a capacity of tens of thousands of units per hour, with the precise movements of the intelligent equipment resembling a precise "relay of life".

Strategic Leap: From "Global Leader in Antiserum" to "Human Medicine + Veterinary Medicine Dual-Wheel Leadership"

At the subsequent exchange meeting, Chairman Jing Yue, under the theme of "Fifty Years of Dedication to Dream Building, Leading Biopharmaceutical Innovation," systematically reviewed the development of Jiangxi Bio. "After more than fifty years of accumulation, the company has grown into the world's largest supplier of human TAT." The data presented by Jing Yue was impressive: the company's domestic market share of human TAT has remained above 50% for 18 consecutive years, and exports cover more than 30 countries and regions.

“We not only focus on human antiserum, but also have built a product matrix driven by a dual-wheel strategy of 'human medicine + veterinary medicine'." Jing Yue introduced that the company's new products under research have started clinical trials, and the subsidiary's veterinary antitoxin is expected to be put into production in the second half of the year. "In the next five years, more than 10 new drugs covering multiple fields will be gradually launched, continuously expanding the application boundaries of biopharmaceuticals."

Cross-Border Debate: The Path to Industrial Innovation Breakthrough from a Technology Management Perspective

In the discussion session, students from the second phase, drawing on their technology management research background, engaged in enthusiastic discussions with the company's management on topics such as "technology transformation," "market expansion," and "internationalization layout." The clash of ideas sparked like wildfire. "As a national high-tech enterprise, how do you balance basic research and commercialization?" a student asked. Jing Yue calmly responded: "Our research and development center in Shenzhen will focus on cutting-edge technologies, while simultaneously accelerating clinical transformation through the GLP platform of the Hainan Pharmaceutical Research Institute. The entire chain from 'basic research - pilot testing - industrialization' has been shortened to 70% of the industry average, allowing innovative results to benefit patients faster."

Regarding the question of "how to mitigate risks in the dual-wheel drive strategy," Jing Yue further added: "The PMSG products in the veterinary medicine sector are linked to the pig and poultry farming cycles, while the TAT in the human medicine sector is a rigid demand, and the two complement each other." The students unanimously expressed that this visit not only allowed them to directly experience Jiangxi Bio's global leading position in the antiserum field, but also gave them a profound understanding of strategies such as "full industry chain integration" and "deep cultivation of niche markets." "From a solid position in the domestic market to strong export performance, Jiangxi Bio's practice provides a valuable example for technology companies to 'occupy niche tracks and build moats,'" summarized one student, echoing the sentiments of everyone present.

Science and Technology Symphony: The Two-Way Rush of Industry and Academia on Red Soil

This visit to Jiangxi Bio was an important part of the second phase of the Technology Management Scholars' Jiangxi mobile classroom. It continued the theme of "Red Ji'an" research and study, and through in-depth cooperation with leading companies in the industry, it achieved a closed loop of "theoretical understanding - industrial practice." As Jing Yue said at the end of the exchange: "Biomedicine is a cause related to life and health, and requires a two-way rush of scientific wisdom and industrial spirit." This cross-border dialogue not only opened a new window for the students to observe the industry, but also injected new thinking into the future development of the biopharmaceutical industry through the integration of science and technology and industry. As night fell, the gentle night of Ji'an enveloped the scene, and the students set off on their return journey with a full harvest. This research and study trip, which combined depth and warmth, left a deep impression of innovation and responsibility in everyone's hearts.